Replimune Group Inc.

REPL | NASDAQ

Price Alert Chart Builder DCF Calculator

$12.87

-$0.20 (-1.53%)

At close: Sep 21, 2026, 4:00 PM ET

$12.87

$0 (0.00%)

Pre-market: Sep 22, 2026, 5:25 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-1.53%

(1D)

Rating

Updated: Aug 13, 2026

23.5

Fundamentals Weak

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $1.08B

1D Range

12.76 13.28

52W Range

1.50 16.33

Valuation (TTM)

PE -4.09

PB 10.24

EV/EBITDA -3.12

Valuation (NTM)

Forward PE N/A

Forward PEG 0.12

Price Target $18.67

Cash Flow

FCF Yield -25.9%

SBC Adj. FCF Yield -28.8%

SBC Impact -11.1%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y 3.0% | -4.6%

FCF 3Y | 5Y -18.7% | -23.4%

Returns

ROA -117.7%

ROE -159.3%

ROIC -136.1%

Financial Health

Net Cash

$167.47M

Current Ratio 5.23

Interest Coverage -31.46

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platf...

Sector Healthcare

Industry Biotechnology

Employees 465

IPO Date Jul 19, 2018

Website www.replimune.com

Fiscal Year April - March

Full Company Profile

Latest News

3 days ago · gurufocus.com

REPL Stockholders with Significant Losses Should Contact Robbins LLP Before the Pending October 5, 2026 Lead Plaintiff Deadline for Information About Recovering Their Losses

REPL Stockholders with Significant Losses Should Contact Robbins LLP Before the Pending October 5, 2026 Lead Plaintiff Deadline for Information About Recovering

4 days ago · globenewswire.com

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) and certain of its officers.

4 days ago · prnewswire.com

REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt

A chronology of Replimune's RP1 regulatory disclosures alleges that between October 20, 2025 and April 10, 2026, investors were told the FDA resubmission was on track while previously communicated study-design concerns allegedly remained unresolved. NEW YORK, Sept.

4 days ago · prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL

NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL).

5 days ago · globenewswire.com

DEADLINE ALERT for REPL, DVLT, and UWMC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

LOS ANGELES, Sept. 16, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.

5 days ago · prnewswire.com

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL

Replimune told investors its RP1 resubmission was a complete response to the FDA's prior deficiency letter and that commercial launch teams stood ready; the agency's April 2026 rejection letter stated the study design concerns it had previously communicated were never addressed, and REPL shares fell to $1.70. NEW YORK, Sept.

6 days ago · globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL

NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

6 days ago · globenewswire.com

Portnoy Law Firm Announces Class Action on Behalf of Replimune Group, Inc. Investors

LOS ANGELES, Sept. 15, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Replimune Group, Inc., (“Replimune” or the "Company") (NASDAQ: REPL) investors of a class action on behalf of investors that bought securities between October 20, 2025 - April 10, 2026, inclusive (the “Class Period”). Replimune investors have until October 5, 2026 to file a lead plaintiff motion.

6 days ago · globenewswire.com

SueWallSt Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - REPL

Important Information Regarding Section 20(a) Individual Liability Claims: CEO Sushil Patel and CFO Emily Hill are named as individual defendants in a securities class action alleging Replimune's RP1 disclosures omitted unresolved FDA study-design concerns Important Information Regarding Section 20(a) Individual Liability Claims: CEO Sushil Patel and CFO Emily Hill are named as individual defendants in a securities class action alleging Replimune's RP1 disclosures omitted unresolved FDA study-design concerns